Compare Ascendis Pharma A/S (ASND) vs MPLX LP (MPLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs MPLX LP — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while MPLX LP trades at $57.11 (market cap $57.79B). The key difference: MPLX LP is far larger — about 3.3× Ascendis Pharma A/S's market cap, and MPLX LP pays a 7.56% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MPLX | |
|---|---|---|
Market Cap | $17.74B | $57.79B |
Sector | Health | Technology |
52-Week High | $277.18 | $59.17 |
52-Week Low | $163.32 | $47.80 |
Enterprise Value | $18.11B | $82.42B |
Dividend Yield | — | 7.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MPLX trades at $56.95, down 0.42% on the day, with a bullish technical outlook supported by moving averages and key support at $56. The company reported strong profitability with a 41.24% net income margin and a trailing P/E of 12.33. Recent earnings showed beats in Q3 and Q4 2025 but a miss in Q1 2026, with Q2 results pending. A $1.08 dividend for H1-26 underscores its income appeal, while analyst consensus remains strongly positive with a $60.60 price target.
The outlook for MPLX is favorable, driven by stable cash flows from fee-based midstream operations and a high dividend yield. Risks include exposure to energy market volatility and a high debt-to-asset ratio of 90.06%. With 71% of analysts rating it a Buy and solid fundamentals, the stock presents a compelling opportunity for income-focused investors, though macroeconomic headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
